Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CERO THERAPEUTICS HOLDINGS, INC. | Chief Executive Officer, Director | Stock Option (Right to Buy) | 1.32M | Mar 25, 2024 | Direct | ||
CERO THERAPEUTICS HOLDINGS, INC. | Chief Executive Officer, Director | Common Stock | 249K | Feb 14, 2024 | Atwood-Edminster Trust dtd 4-2-2000 | ||
Clovis Oncology, Inc. | Director | Stock Option (right to buy) | 42.2K | Jun 10, 2021 | Direct | ||
Atreca, Inc. | Director | Stock Option (right to buy) | 12K | Jun 13, 2023 | Direct | ||
CERO THERAPEUTICS HOLDINGS, INC. | Chief Executive Officer, Director | Series A Convertible Preferred Stock | 1K | Feb 14, 2024 | Atwood-Edminster Trust dtd 4-2-2000 |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LPAA | Launch One Acquisition Corp. | Jul 11, 2024 | 0 | $0 | 3 | Jul 11, 2024 | Director |
CERO | CERO THERAPEUTICS HOLDINGS, INC. | Mar 25, 2024 | 1 | $0 | 4 | Mar 27, 2024 | Chief Executive Officer, Director |
CERO | CERO THERAPEUTICS HOLDINGS, INC. | Feb 14, 2024 | 4 | $1M | 4/A | Mar 11, 2024 | Chief Executive Officer, Director |
CERO | CERO THERAPEUTICS HOLDINGS, INC. | Feb 14, 2024 | 3 | $1M | 4/A | Feb 21, 2024 | Chief Executive Officer, Director |
CERO | PHOENIX BIOTECH ACQUISITION CORP. | Feb 14, 2024 | 4 | $1M | 4 | Feb 16, 2024 | Chief Executive Officer, Director |
BCEL | Atreca, Inc. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
BCEL | Atreca, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 13, 2022 | Director |
PBAX | PHOENIX BIOTECH ACQUISITION CORP. | Oct 8, 2021 | 1 | $0 | 4 | Oct 12, 2021 | Director |
PBAX | PHOENIX BIOTECH ACQUISITION CORP. | Oct 5, 2021 | 0 | $0 | 3 | Oct 5, 2021 | Director |
CLVS | Clovis Oncology, Inc. | Jun 10, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |
BCEL | Atreca, Inc. | Jun 9, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |